PURPOSE: To present clinical findings of a cluster of cases of inadvertent high-dose intracameral cefuroxime injection after uneventful phacoemulsification cataract surgery. METHODS: Six eyes of 6 patients (mean age 68.33 years, range 61-75, 4 male, 2 female) were operated on the same day by the same surgeon. At the end of surgery, 3 mg in 0.1 mL cefuroxime (30 mg/mL, Zinnat, GlaxoSmithKline) was erroneously injected into anterior chamber of 6 eyes. Incorrect dilution of cefuroxime was noticed at the end of operation day. RESULTS: The 6 patients were followed up very closely every day during the first week. No adverse reaction or inflammation was observed at postoperative examination. All patients achieved 20/20 or better vision at the end of the first week. CONCLUSIONS: Inadvertent intracameral (3 mg in 0.1 mL) cefuroxime injection did not cause any detectable adverse effect on ocular tissues.
PURPOSE: To present clinical findings of a cluster of cases of inadvertent high-dose intracameral cefuroxime injection after uneventful phacoemulsification cataract surgery. METHODS: Six eyes of 6 patients (mean age 68.33 years, range 61-75, 4 male, 2 female) were operated on the same day by the same surgeon. At the end of surgery, 3 mg in 0.1 mL cefuroxime (30 mg/mL, Zinnat, GlaxoSmithKline) was erroneously injected into anterior chamber of 6 eyes. Incorrect dilution of cefuroxime was noticed at the end of operation day. RESULTS: The 6 patients were followed up very closely every day during the first week. No adverse reaction or inflammation was observed at postoperative examination. All patients achieved 20/20 or better vision at the end of the first week. CONCLUSIONS: Inadvertent intracameral (3 mg in 0.1 mL) cefuroxime injection did not cause any detectable adverse effect on ocular tissues.
Authors: Randy C Bowen; Andrew Xingyu Zhou; Sailaja Bondalapati; Thomas W Lawyer; Karisa B Snow; Patrick R Evans; Tyler Bardsley; Mary McFarland; Matthew Kliethermes; Dallas Shi; Christina A Mamalis; Tom Greene; Christopher J Rudnisky; Balamurali Krishna Ambati Journal: Br J Ophthalmol Date: 2018-01-11 Impact factor: 4.638